BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 2095753)

  • 1. Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment.
    Yamada M; Wasserman R; Lange B; Reichard BA; Womer RB; Rovera G
    N Engl J Med; 1990 Aug; 323(7):448-55. PubMed ID: 2095753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
    N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of minimal residual disease in B-cell lineage acute lymphoblastic leukemia of childhood, using clone-specific probes.
    Botsonis T; Tsangaris GT; Mikraki V; Tzortzatou-Stathopoulou F
    Anticancer Res; 1999; 19(3B):2211-20. PubMed ID: 10472333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia.
    Roberts WM; Estrov Z; Ouspenskaia MV; Johnston DA; McClain KL; Zipf TF
    N Engl J Med; 1997 Jan; 336(5):317-23. PubMed ID: 9011783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse.
    Biondi A; Yokota S; Hansen-Hagge TE; Rossi V; Giudici G; Maglia O; Basso G; Tell C; Masera G; Bartram CR
    Leukemia; 1992 Apr; 6(4):282-8. PubMed ID: 1316978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia.
    Uckun FM; Kersey JH; Haake R; Weisdorf D; Nesbit ME; Ramsay NK
    N Engl J Med; 1993 Oct; 329(18):1296-301. PubMed ID: 8413410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paucity of leukemic progenitor cells in the bone marrow of pediatric B-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse.
    Uckun FM; Gaynon PS; Stram DO; Sensel MG; Sarquis MB; Lazarus KH; Willoughby M
    Clin Cancer Res; 1999 Sep; 5(9):2415-20. PubMed ID: 10499612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
    Uckun FM; Stork L; Seibel N; Sarquis M; Bedros C; Sather H; Sensel M; Reaman GH; Gaynon PS
    Clin Cancer Res; 2000 Aug; 6(8):3123-30. PubMed ID: 10955793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of minimal residual disease in patients with childhood common acute lymphoblastic leukemia after autologous bone marrow transplantation with ex vivo purging and systemic IL-2 infusion: unsuccessful prediction of subsequent relapse.
    Kiyoi H; Kojima S; Kato K; Matsuyama T; Kodera Y; Ohno R; Naoe T
    Bone Marrow Transplant; 1995 Sep; 16(3):437-42. PubMed ID: 8535317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early resistance to therapy during induction in childhood acute lymphoblastic leukemia.
    Brisco MJ; Sykes PJ; Dolman G; Hughes E; Neoh SH; Peng L; Snell LE; Toogood IR; Rice MS; Morley AA
    Cancer Res; 2000 Sep; 60(18):5092-6. PubMed ID: 11016634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia.
    Ito Y; Wasserman R; Galili N; Reichard BA; Shane S; Lange B; Rovera G
    J Clin Oncol; 1993 Mar; 11(3):546-53. PubMed ID: 8445430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
    Chan DW; Liang R; Kwong YL; Chan V
    Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia.
    Kitchingman GR
    Leukemia; 1994 Mar; 8(3):395-401. PubMed ID: 8127144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular evidence for minimal residual bone marrow disease in children with 'isolated' extra-medullary relapse of T-cell acute lymphoblastic leukemia.
    Neale GA; Pui CH; Mahmoud HH; Mirro J; Crist WM; Rivera GK; Goorha RM
    Leukemia; 1994 May; 8(5):768-75. PubMed ID: 8182934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of minimal residual disease using clonospecific primers for CDRIII in patients with acute B lymphocytic leukemia with or without Philadelphia chromosome: possibility of clinical application as a tool for improving prognosis.
    Maeda Y; Horiuchi F; Morita S; Matsuda M; Shirakawa C; Masaki H; Koyama A; Hamazaki H; Fujimoto T; Irimajiri K
    Exp Hematol; 1994 Aug; 22(9):881-7. PubMed ID: 8062887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
    Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
    Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia.
    Estrov Z; Ouspenskaia MV; Felix EA; McClain KL; Lee MS; Harris D; Pinkel DP; Zipf TF
    Leukemia; 1994 Jan; 8(1):46-52. PubMed ID: 8289497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
    Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
    Bone Marrow Transplant; 2000 Apr; 25(8):843-51. PubMed ID: 10808205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of minimal residual disease in high risk childhood acute lymphoblastic leukemia using an immunological approach during complete remission. AIEOP Cooperative Group for Immunology of Acute Leukemias.
    Consolini R; Scamardella F; Legitimo A; Putti C; Granchi D; Paolucci P; Lippi A; Guazzelli C; Acquaviva A; Rosanda C
    Haematologica; 1993; 78(5):297-305. PubMed ID: 8314159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.